Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.4 HKD | -2.27% | -4.18% | -19.53% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.53% | 7.32B | B- | ||
-0.92% | 89.87B | A- | ||
-1.05% | 37.57B | A- | ||
-11.20% | 32.75B | B- | ||
+61.85% | 26.47B | A | ||
-20.75% | 14.25B | C | ||
-6.35% | 12.99B | B- | ||
-11.42% | 11.93B | D+ | ||
-47.67% | 10.84B | B | ||
+5.99% | 9.11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1801 Stock
- Ratings Innovent Biologics, Inc.